Table 1 Estimated overall survival probability at specified time-points (final analysis).

From: First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

Time-point (months)

Overall survival probability (95% CI)

 

TT-B (n = 77)

C-B (n = 76)

6

0.86 (0.76–0.92)

0.83 (0.72–0.90)

12

0.76 (0.65–0.84)

0.67 (0.55–0.76)

18

0.63 (0.51–0.73)

0.47 (0.35–0.57)

24

0.39 (0.28–0.50)

0.34 (0.24–0.45)

  1. C-B capecitabine plus bevacizumab, CI confidence interval, TT-B trifluridine/tipiracil plus bevacizumab.
Back to article page